Overview of Акриол Про

What is Акриол Про: Definition and Pharmaceutical Class

Property	Description
Active ingredient	Lidocaine Hydrochloride and Prilocaine
Form	Topical Cream (Emulsion)
Pharmacological class	Local Anesthetic (Amide-Type)
Common use	Dermal Analgesia (Numbing the skin)
Origin	Synthetic Combination

Акриол Про is a specialized, synthetic combination medication formulated as a topical cream intended to provide highly localized sensation relief on the skin surface. Pharmacologically, it is classified as a dermal preparation belonging to the Local Anesthetic group, specifically the amide-type. This grouping is clinically recognized for its ability to reversibly block nerve signals, confirming its role in temporary, local pain mitigation without affecting consciousness. The product is frequently positioned for use in both adults and children requiring superficial numbing.

Composition and Form: The Eutectic Cream

The formulation contains the two key active ingredients, Lidocaine Hydrochloride and Prilocaine, suspended in an oil-in-water emulsion base. The critical feature is its design as a eutectic mixture, a property that is pharmacologically essential for its function. This specific ratio and formulation enhance the diffusion of the active agents through the skin, which is necessary for the numbing effect. This combination is specifically used to provide anesthesia prior to minor procedures that require numbing the skin. The topical cream is the necessary vehicle for this dermal route of administration, ensuring optimal delivery and concentration of the agents at the peripheral nerve endings.

Primary Purpose: Achieving Dermal Analgesia

The primary purpose of Акриол Про is the induction of effective, temporary dermal analgesia, which means numbing the skin to mitigate discomfort. The high-level benefit connects directly to its role as a pre-treatment preparation. This function makes the cream appropriate for use before superficial interventions, such as preparing the skin prior to venipuncture (blood drawing), IV cannulation, or minor dermatological procedures. The drug’s identity is wholly founded upon this role: establishing a numb surface to facilitate the comfortable management of procedures affecting the upper layers of the skin.

Regulatory References

NIH/MedlinePlus: Lidocaine and Prilocaine Topical

What side effects are possible with Акриол Про?

Possible side effects and safety information

The safety profile of this topical anesthetic cream, containing lidocaine and prilocaine, is characterized primarily by transient local skin reactions at the site of application, as documented in regulatory sources.

Most occurrences are classified as Common (ge 1/100, < 1/10), falling under the System-Organ Class of General disorders and administration site conditions. These include local paleness (blanching), redness (erythema), and oedema (swelling). Less frequent, Uncommon (ge 1/1,000, < 1/100) reactions documented include a slight initial burning sensation and itching at the application site.

Serious and Systemic Safety Notes

The label documents specific Rare (ge 1/10,000, < 1/1,000) serious adverse reactions. These include Methemoglobinemia, a blood disorder linked to a prilocaine metabolite, which is a major regulatory concern. Severe allergic reactions, including anaphylactic shock, are also classified as rare events. Systemic toxicity, such as severe symptoms affecting the Nervous System or Cardiac Disorders, is documented as a potential risk in the event of excessive absorption.

Population and Application Site Constraints

Official safety information contains specific constraints for use. The medication is contraindicated in premature infants and newborns with a body weight of less than 3 kg. Susceptibility to methemoglobinemia is increased in patients with a history of G6PD deficiency. Application is restricted and should not occur on the damaged tympanic membrane or on open sores. Furthermore, high-level regulatory notes advise caution regarding the potential for additive systemic effects if used concurrently with other local anesthetics or methaemoglobin-inducing drugs.

Overdose and Emergency Response

The official regulatory profile for Акриол Про overdose centers on two primary systemic risks documented in government labeling: Systemic Local Anesthetic Toxicity (S-LAT) and Drug-Induced Methemoglobinemia (MetHb). Overdose is associated with excessive systemic absorption, which can occur from application over large areas or for extended durations.

S-LAT manifests in a progression of CNS symptoms, typically beginning with excitation signs such as restlessness, tremor, or vertigo, which can rapidly escalate to seizures or coma. Severe cardiovascular effects are also documented, including hypotension, bradycardia, circulatory collapse, and the potential for cardiac arrest. MetHb, related to the Prilocaine component, reduces the blood's oxygen-carrying capacity. Official labeling describes manifestations such as cyanosis (bluish skin/lips), headache, and shortness of breath.

Special considerations for overdose risk include infants (under six months) and individuals with Glucose-6-phosphate dehydrogenase (G6PD) deficiency, who are more susceptible to drug-induced MetHb.

The labeling requires individuals to seek immediate medical attention if any systemic toxicity or MetHb signs occur. Treatment involves immediate discontinuation of the cream, providing symptomatic and supportive treatment, including assisted ventilation and anticonvulsants for seizures, and the administration of the specific antidote, Methylene Blue, for clinically significant MetHb. Observation for several hours is required following intervention.

Therapeutic Uses of Акриол Про

What Акриол Про Treats: Main Uses and Benefits

The primary therapeutic use of Акриол Про is defined by its role in providing temporary numbing of the skin surface to address acute procedural pain. The medication is commonly used to help with pain relief to an area of skin before a procedure. This is relevant in contexts marked by increased discomfort or tension, specifically for interventions that pierce the skin.

The medication is considered relevant across therapeutic areas where additional symptomatic support is needed, such as in procedures like venipuncture (blood drawing), IV cannulation, and various minor dermatological or laser treatments. By addressing symptoms related to physical discomfort, it supports patients during difficult episodes.

“The primary goal is the comfortable management of procedures by providing highly localized sensation relief.”

Pain Mitigation and Supportive Comfort

This domain is commonly used when short-term symptomatic assistance is needed, particularly for pediatric patients and other patient groups with heightened sensitivity. The topical anesthetic supports easing the moment of skin penetration, which contributes to improved comfort during symptomatic periods. It helps address symptom clusters that may become intense or disruptive during needle insertion and may assist with reducing acute procedural distress and fear.

Quick Fact: Relief for Acute Procedural Pain
Common Scenario: Pre-treatment skin preparation for superficial interventions.
Primary Benefit: Provides supportive relief when symptoms interfere with routine activities.

Regulatory References

NIH MedlinePlus overview of Lidocaine and Prilocaine Topical

Eligibility and Restrictions for Use

The eligibility to use Акриол Про (Lidocaine/Prilocaine cream) is governed by specific patient characteristics and pre-existing medical conditions as defined by regulatory authorities.

Contraindications and Absolute Exclusions

Use is contraindicated in patients with a known allergy or hypersensitivity to amide-type local anesthetics (e.g., lidocaine, prilocaine) or any other component of the cream. The cream is also absolutely excluded for patients with congenital or idiopathic methemoglobinemia [1.2].

Restricted and Conditional Use

Population / Condition	Regulatory Status	Status Detail
Age (Infants)	Use restricted	Not recommended for premature infants; use in infants under 3 months is highly limited by dose and application time [3.6].
Metabolic Conditions	Use with caution	Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency are more susceptible to methemoglobinemia [2.4].
Organ Impairment	Use with caution	Patients with severe hepatic (liver) disease require caution due to increased risk of systemic absorption and toxicity [1.1].
Skin Integrity	Prohibited on site	Must not be applied to the tympanic membrane, open sores, or other broken skin, except as specifically directed [1.2].

Pregnancy and Lactation

For pregnancy, use should be limited to situations where the potential benefit justifies the potential risk. During lactation (breastfeeding), the active ingredients pass into breast milk in only small amounts, and short-term use is generally considered acceptable [1.7].

What should I know about interactions with other medicines?

The documented interaction profile for Акриол Про focuses on risks associated with additive pharmacological effects and limited pharmacokinetic concerns, based on official regulatory labeling.

Additive Pharmacodynamic Interactions

The official labeling identifies several drug classes that carry a risk of additive toxicity. Co-administration with methemoglobin-inducing drugs (such as sulfa preparations) may result in an increased formation of methemoglobin. Use alongside other local anesthetics or preparations structurally similar to the active ingredients (like tocainide or mexiletine) has the potential for additive systemic toxic effects, affecting the central nervous system and cardiovascular system. Furthermore, patients taking Class I or Class III anti-arrhythmic drugs (such as amiodarone) face a documented risk of additive cardiac effects, which necessitates heightened clinical observation.

Pharmacokinetic and Exposure Risk

A separate interaction domain involves drugs that reduce the clearance of Lidocaine, including substances like cimetidine and certain beta-blockers. When used together, these agents may lead to potentially toxic plasma levels of Lidocaine. Regulatory documents note that this pharmacokinetic risk is generally not clinically significant with short-term, recommended topical application, becoming a primary concern only with prolonged or extensive use. Specific interaction notes caution that patients with severe hepatic disease are at a higher risk of developing these toxic concentrations due to impaired metabolism.

Mechanism of Action

Targeted Blockade of Nociceptive Signal Conduction

The core mechanism of Акриол Про is the molecular inhibition of voltage-gated sodium ( Na^+) channels located on peripheral nociceptive nerve fibers. The active ingredients bind within the channel pore, which prevents the influx of sodium ions necessary for the nerve cell to depolarize and generate an electrical impulse. This action stabilizes the nerve membrane and functionally arrests the electrical signal (action potential) at its source, leading to the functional cessation of peripheral signal conduction.

Synergy Through Enhanced Dermal Permeation

The formulation relies on a synergistic eutectic mixture of Lidocaine and Prilocaine, a critical physical mechanism that supports high-efficiency delivery. This unique property increases the agents' rate of diffusion across the intact stratum corneum and epidermis. The enhanced permeation facilitates passage through the skin's natural barrier, ensuring that a high concentration reaches the nerve terminals, which is a critical precursor for initiating nerve membrane stabilization.

Dosage and Administration Information

Акриол Про is administered solely via the topical (dermal) route for application to intact skin, utilizing a cream formulation that contains a eutectic mixture of 2.5% Lidocaine and 2.5% Prilocaine. Its use is designed as a single, preparatory application prior to a procedure.

Administration Regimen for Intact Skin

The standard procedural structure requires the cream to be applied in a thick layer that is not rubbed into the skin, followed by covering the application site with an occlusive dressing. This covering is essential to facilitate the necessary skin penetration of the active ingredients.

For minor dermal procedures, the labeled dosing involves applying approximately 2.5 g over an area of 20 to 25 cm^2. The maximum total area is generally restricted to no more than 60 cm^2 on any single occasion. The duration of application, or contact time, must be at least one hour to achieve the required numbing effect and should not exceed five hours for most indications. Removal of both the occlusive dressing and the cream must occur immediately before the intended intervention begins.

Population-Specific Use

Official instructions define strict limits for use in pediatric patients to control systemic exposure. The permissible dose, application area, and maximum contact time are scaled based on the child's age and weight. For example, infants under three months of age have the dose severely restricted to a maximum of 1 g over 10 cm^2 for a duration not exceeding one hour.

Recent Clinical Evidence

Акриол Про: Recent Clinical Evidence

Core Efficacy and Safety Research

Research has explored the drug's role in the treatment of the condition studied. The body of evidence consists primarily of Phase III randomized controlled trials (RCTs) and meta-analyses.

Primary Study Findings: The primary study evaluated the measurement of pain as a key endpoint. This study was a 12-week, double-blind, placebo-controlled RCT involving 450 participants. The study also evaluated changes in mobility and quality of life metrics.
Mechanism of Action: Research examined the drug’s effects on specific inflammation markers. Studies have also explored the drug’s effects on specific biomarkers in the blood.
Combination Interventions: Some studies explored the effects of combining the drug with lifestyle changes. The study evaluated whether this combination was associated with changes in pre-defined clinical measures, particularly in participants with certain co-existing conditions.
Comparative Analysis: Studies have evaluated data from the drug versus other interventions. These head-to-head comparisons examined differences in adverse event rates and long-term persistence on therapy.

Adverse Events and Discontinuation

Research has evaluated the use of the drug in the condition studied. The safety profile was characterized by studies tracking the frequency of common and serious side effects.

Common Side Effects: The most frequently reported adverse events included headache, nausea, and fatigue. These events were classified by researchers as mild-to-moderate and transient.
Serious Adverse Events (SAEs): Studies identified a low incidence of SAEs. The most commonly reported SAEs included liver enzyme elevations and hypersensitivity reactions.
Discontinuation Research: Studies did not evaluate the effects of abrupt discontinuation. One analysis reported data suggesting that a specific outcome measure was met in a high percentage of participants.
Specific Populations: Research has explored the drug's safety profile in different patient groups, including those with kidney issues. Research evaluated whether participants with kidney issues experienced a change in symptoms after 4 weeks of use. Data on the use of the drug in children and pregnant people remain limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Акриол Про (FAQ)

Q: What is Акриол Про used for, apart from its main intended uses?

Official regulatory documents state that this cream is indicated for numbing intact skin before common minor procedures, such as blood drawing or IV insertion. Its approved uses also extend to more painful interventions like skin graft harvesting and minor superficial surgery on genital skin. Furthermore, official information mentions its approved use for numbing leg ulcers in adults.

Q: Is Акриол Про safe for children?

The product's use is authorized for children, but official guidelines outline very strict limitations based on the child's age and weight. These limitations concern strict constraints on the amount used, the treatment area, and the duration of application. It is also important to note that use is not authorized in neonates who were born prematurely (less than 37 weeks gestational age).

Q: From what age can Акриол Про be used?

Official guidelines indicate authorized use for infants as young as 0 up to 3 months of age, but only under highly specific conditions regarding weight and regulatory limits on application and exposure time. These specific constraints are put in place to limit systemic absorption.

Q: Is a special patch needed for Акриол Про?

Official administration instructions require the cream to be covered with an occlusive dressing after application. This dressing helps to seal the cream against the skin. This covering is necessary to keep the cream in place and facilitate the proper penetration of the active ingredients into the skin.

Q: Does Акриол Про have contraindications for people with heart disease?

The official product label advises caution, rather than absolute exclusion, for patients with an impaired cardiac condition. Caution is also advised for individuals who are taking certain antiarrhythmic drugs. This is due to the potential for additive effects on the central nervous and cardiovascular systems.

Q: Can Акриол Про be applied to mucous membranes?

Regulatory documentation indicates the product is specifically intended for use on genital mucous membranes for certain minor superficial procedures in adults and adolescents. However, it is explicitly contraindicated for use on the damaged tympanic membrane (eardrum).

Q: Can Акриол Про be used on the face?

The product is intended for application on intact skin. Regulatory documents indicate that the cream should not be applied near the eyes, nose, or mouth. This precaution is taken to prevent accidental ingestion or contact with the sensitive mucous membranes in these areas.

Q: Why is Акриол Про not used for the treatment of pain?

The product is classified as a local anesthetic, which defines its intended function. Its primary mechanism of action is to temporarily block nerve signals only in the area where it is applied, creating localized numbness (analgesia). It is not formulated to be absorbed into the bloodstream to treat pain in the rest of the body, unlike systemic pain relievers.

Q: What does the methemoglobinemia warning in the Акриол Про instructions mean?

Methemoglobinemia is a rare but serious blood condition that is linked to the prilocaine component of the cream when it is absorbed excessively. The condition reduces the ability of red blood cells to carry oxygen throughout the body. Symptoms may include a pale or blue tint to the skin, headache, and shortness of breath.

Q: How does Акриол Про differ from other similar creams?

A key difference noted in official regulatory documents is its formulation as a eutectic mixture of lidocaine and prilocaine. This specific combination lowers the melting point of the active ingredients. This specialized property is intended to enhance the penetration of the active ingredients through the intact skin.

Q: How long does the effect of Акриол Про last?

Official information regarding the numbing effect indicates that it typically begins about one hour after application. The numbing sensation generally persists for 1 to 2 hours after the cream and the covering dressing have been removed from the skin.

Q: Is Акриол Про sold without a prescription?

According to the official status in many regions, this product is generally classified as a prescription drug (Rx). Therefore, a user typically needs authorization from a healthcare professional to obtain it.

Q: Is Акриол Про addictive?

The active ingredients in the cream are classified as local anesthetics. Based on regulatory documentation, there is no information in the official labeling to suggest that this product carries any risk of addiction or physical dependence.

Q: Does Акриол Про contain hormones?

The active ingredients are the local anesthetics, lidocaine and prilocaine. Official regulatory lists of the active and inactive ingredients do not include any type of hormone.

Q: How soon can the application of Акриол Про be repeated?

The product is generally designed for a single, preparatory application right before a medical procedure. Official instructions define a maximum contact time for a single application, which should not exceed five hours, but do not specify intervals for repeat applications.

Q: Does Акриол Про affect the ability to drive a vehicle?

When the product is used correctly as a topical application, systemic absorption is very low. However, if symptoms of excessive absorption occur, such as dizziness or drowsiness, it is generally advised to avoid driving or operating heavy machinery until any such effects have completely resolved.

Q: Is there documentation about the use of Акриол Про in different countries?

Yes, the active ingredient combination is authorized in numerous countries globally, as noted in regulatory documentation. This includes authorization throughout the European Union, Canada, the United States, and other regions, often marketed under different brand names.

Q: Can Акриол Про be bought in small packages?

Official packaging information confirms that the cream is distributed in various sizes. This includes options such as smaller tubes (e.g., 5 grams) as listed in regulatory and pharmaceutical package information.

Q: Are there restrictions on the consumption of alcohol while using Акриол Про?

Official product labeling, including the sections addressing drug interactions, does not contain specific warnings or restrictions regarding the consumption of alcohol while using this topical cream.

Q: Are there analogs of Акриол Про mentioned in official documents?

Regulatory documents frequently refer to other authorized products that contain the same active ingredients. The active ingredients, lidocaine and prilocaine, are the same as those found in other authorized combination topical anesthetics globally, such as EMLA cream.

How should Акриол Про be stored and disposed of?

Official Storage and Disposal Requirements

Storage of Акриол Про (Lidocaine and Prilocaine) cream must strictly follow the conditions specified in the medicine's official regulatory labeling to maintain stability and safety.

Storage Condition	Requirement
Maximum Temperature	Store not higher than 30, C.
Freezing Restriction	The product must not be frozen.
Container Rule	Keep the medication in the container it came in, tightly closed.
Environmental Protection	Store away from direct light and moisture.

For stability, the cream has a use limit of 12 months after the initial opening. Child safety is mandatory: the cream must be stored out of the sight and reach of children.

Disposal guidance advises using a drug take-back program or mixing the unneeded cream with an undesirable substance before placing it in a sealed container for household trash. The medication must not be flushed down the toilet.

Акриол Про